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Abstract
Background: The boundaries between health-related research and practice have become blurred as initiatives
traditionally considered to be practice (e.g., quality improvement, program evaluation) increasingly use the same
methodology as research. Further, the application of different ethical requirements based on this distinction
raises concerns because many initiatives commonly labelled as “non-research” are associated with risks to patients,
participants, and other stakeholders, yet may not be subject to any ethical oversight. Accordingly, we sought to
develop a tool to facilitate the systematic identification of risks to human participants and determination of risk level
across a broad range of projects (e.g., clinical research, laboratory-based projects, population-based surveillance, and
program evaluation) and health-related contexts. This paper describes the development of the Public Health Ontario
(PHO) Risk Screening Tool.
Method: Development of the PHO Risk Screening Tool included: (1) preparation of a draft risk tool (n = 47 items);
(2) expert appraisal; (3) internal stakeholder validation; (4) external validation; (5) pilot testing and evalution of the
draft tool; and (6) revision after 1 year of testing.
Results: A risk screening tool was generated consisting of 20 items organized into five risk domains: Sensitivity;
Participant Selection, Recruitment and Consent; Data/Sample Collection; Identifiability and Privacy Risk; and Commercial
Interests. The PHO Risk Screening Tool is an electronic tool, designed to identify potential project-associated risks to
participants and communities and to determine what level of ethics review is required, if any. The tool features an easy
to use checklist format that generates a risk score (0–3) associated with a suggested level of ethics review once all items
have been completed. The final score is based on a threshold approach to ensure that the final score represents the
highest level of risk identified in any of the domains of the tool.
Conclusions: The PHO Risk Screening Tool offers a practical solution to the problem of how to maintain accountability
and appropriate risk oversight that transcends the boundaries of research and practice. We hope that the PHO Risk
Screening Tool will prove useful in minimizing the problems of over and under protection across a wide range of
disciplines and jurisdictions.
Keywords: Risk screening tool, Risk assessment, Risk, Ethics, Research, Quality improvement, Program evaluation, Evidence
generating, Learning healthcare, Public Health
Background
Traditionally, the distinction between research and practice
has been the factor that determines whether formal ethical
scrutiny is applied to human subjects-related inquiries [1].
This long-accepted distinction has shaped the develop-
ment of research ethics regulations, guidelines, and institu-
tional infrastructure supporting ethics oversight, which
have been targeted exclusively to initiatives meeting a
definition of “research”. As a result of operational and
ethical challenges, however, the appropriateness of this
dichotomous approach has increasingly been called into
question.
Operationally, implementing procedures for ethics re-
view requires the development of definitions or criteria to
separate research from practice. In reality, however, the
boundary between these two activities is not clear, and
attempts to develop criteria to reliably separate them have
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proven unsatisfactory [2–4]. The blurring of boundaries
between research and practice has worsened in recent
years, as initiatives traditionally considered practice, such
as quality improvement and program evaluation, increas-
ingly use the same rigorous methodologies as research [5].
Moreover, current trends toward the transition of medical
care to a “learning health care system” [6], in which the
provision of care is closely integrated with observational
and comparative effectiveness research [7] or other prag-
matic clinical trials [8], further challenges the research-
practice distinction.
Apart from the challenge in identifying criteria to reliably
distinguish between research and practice, the application
of different ethical requirements based on this distinction
raises ethical concerns because many of the initiatives that
are commonly labelled as “non-research” are associated
with risks to patients, participants, and other stakeholders
yet may not be subject to any form of ethical oversight
[3, 9–11]. Concern that there has been over protection in
some areas and under protection in others has led to calls
for the creation of “a new ethical foundation…that pro-
vides oversight that, rather than being based on a distinc-
tion between research and practice, is commensurate with
risk and burden in both realms” [12].
Adoption of a risk-based system of oversight that applies
to both research and other type of data collection that may
be classified as practice, may address the definitional and
ethical challenges noted above, but raises new questions
regarding how to operationalize such an approach. Key
challenges include determining the level of risk associated
with various initiatives, and what type of oversight is ap-
propriate. In addition, successful adoption of a broader
scope of ethics review requires emphasis on a culture of in-
tegrity, where consideration of the ethical implications is
accepted by project teams as integral to the planning and
conduct of all evidence-generating initiatives involving hu-
man participants, rather than something to be considered
only as needed to comply with externally dictated regula-
tory requirements. The term “evidence-generating initia-
tive” is used here to refer to all projects or activities that
produce information through systematic collection or use
of data about people, their environments, and the health or
social services that they receive or provide.
A number of tools have been developed to assess
research-related risks, but there are limitations in their
ability to support a broader scope of ethics review and
to promote a culture of ethical integrity. Risk matrices
are used by many research institutions to appraise risk
and determine review level (e.g., University of Toronto
[13]), but these are designed to sort projects into one of
two ethics review streams that have been developed spe-
cifically for research (i.e., delegated or full board ethics
review). A simple shunting of all projects into existing
research ethics review mechanisms would not be
appropriate as it would not address concerns about over
protection of very low risk projects, and thus would
create an unnecessary burden for investigators and
ethics oversight systems. Over protection can also inter-
fere with delivery of care, thereby creating rather than
reducing risk. [14]. In addition, matrices require that
users assign a risk level (e.g., low, medium or high) to
the project overall, but do not aid in this assignment
through the identification and rating of risks.
Various screening tools are also in use, which sort pro-
jects based on the presence or absence of procedures
that may be associated with risk, such as the testing of
new medical treatments or the use of questionnaires
probing sensitive issues (e.g., ARECCI [15]; King’s
College London [16]; Vanier College [17]). Although
these tools provide more guidance in the assessment of
risk, currently available versions involve sorting of
projects into “research” or “non-research” designations
to determine the appropriate level of ethics oversight. In
addition, the tools tend to allow for only a “yes” or “no”
response regarding various initiatives, which does not
allow for the incorporation of context into determining
a project’s risk level. For example, collection of direct
identifiers from participants raises privacy concerns that
typically warrant additional scrutiny. However, the level
of concern when identifiers are collected only for the
purose of obtaining and documenting consent, is less
than if findings will be associated with identifiable indi-
viduals. A simple “yes” to collection of direct identifiers
could lead to an overestimation of risk in the first
instance, or an underestimation in the second scenario.
The ability to consider context improves the specificity
of risk assessment, which is valuable in any ethics over-
sight system, but which would be particularly important
in supporting ethics oversight across the research-
practice continuum.
Finally, current screening tools reflect the clinical trials
origins of research ethics guidelines, and focus on risks
mainly from the perspective of individual participants.
These tools are not as sensitive in considering risks to
collectivities that may arise with health-related evidence
generation, particularly in areas such as health services
research, public health, implementation science and
quality improvement initiatives.
To promote routine incorporation of ethical reflec-
tion across health-related settings, we aimed to create a
tool that supports identification of risks and determin-
ation of risk level that would be efficient, user friendly,
and applicable to a broad range of evidence-generating
initiatives (e.g., laboratory-based projects, population-
based surveillance, program evaluation), including re-
search and other practices. In line with these objectives,
this paper describes the development of the Public
Health Ontario (PHO) Risk Screening Tool.
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Setting
PHO is an arm’s length government agency charged with
the protection and promotion of health and the reduction
of health inequities for Ontarians [18]. This mandate is
achieved through the provision of scientific and technical
expertise to clients working across health and non-health
sectors (e.g., government, local public health agencies, pri-
mary care, and professional associations). For example,
PHO supports the development of knowledge syntheses,
tools and best practice guidelines. In addition, because
public health spans a broad range of content areas (e.g.,
infectious disease, chronic disease, and environmental
health) and forms of inquiry (e.g., basic science, clinical
trials, health services evaluation, epidemiology, and popu-
lation health assessment and surveillance), the services
offered by PHO are broad in nature.
As evidence generation is frequently a component of
routine services as well as research initiatives in this
setting, the operational and ethical challenges associated
with differential ethics review for research and practice
arise frequently. As a result, PHO has developed an inte-
grated system of ethics support and oversight for all
evidence-generating health-related initiatives involving
human participants or their personal information and/or
biological materials [19]. The single, integrated system
avoids the challenge of distinguishing between initiatives
of research or practice and employs a proportionate risk
approach, whereby the level of ethical scrutiny applied
to a project reflects the level of risk presented by the
project. The system balances institutional responsibility
for ethics oversight (e.g., by maintaining compliance with
national standards), with the provision of services that
promote consideration of ethical impacts throughout the
life cycle of a project. Importantly, this proportionate risk
approach to ethical appraisal is initiated by use of the
PHO Risk Screening Tool, which supports assignment of
projects to appropriate review levels.
Overview of development process
The PHO Risk Screening Tool was designed to promote
the systematic consideration of risks for all evidence-
generating initiatives involving human participants, their
biological material or their data, regardless of whether
or not they are classified as “research”, and to support a
proportionate approach to ethics review based on risk
rather than project type. Development of the PHO Risk
Screening Tool included a multifaceted strategy leveraging
on the expertise of diverse stakeholders and experts. Spe-
cifically, the development process included: (1) prepar-
ation of a draft risk tool; (2) expert appraisal; (3) internal
stakeholder validation; (4) external validation; (5) pilot
testing and evalution of the draft tool; and (6) revision
after one year of testing.
Preparation of a draft risk tool
A list of activities that may be associated with risk (e.g.,
collection of direct identifiers, use of documents not
available in the public domain, access to private prop-
erty) was generated through consideration of various
ethics guidelines [20] and regulations (e.g., legal mandates
of our organization, provincial privacy legislation), our
organizational ethics framework [21], existing risk tools
[9, 22], and consultation with internal PHO stakeholders.
Consultations with internal stakeholders involved meet-
ings with staff including scientists, epidemiologists, and
physicians from multiple program areas to elicit feedback
about the types of risks that arise in the course of their re-
search and practice. This information was used to inform
the nature and scope of potential risks that occur across
varied health-related contexts. Based on this review and
consultation process, a draft tool was developed. The draft
tool included a hierarchy of 13 primary questions to assess
potential risks and burdens to participants (e.g., does this
activity involve indirect collection or use of personal infor-
mation?), with 23 secondary questions to clarify the pa-
rameters of the potential risk or burden (e.g., will this
information be used to contact identified individuals?),
and 11 tertiary questions to obtain specific, detailed infor-
mation about the potential risk or burden (e.g., who will
make the first contact with identified individuals?).
Expert appraisal
A panel of three reviewers with expertise in research
ethics, clinical medicine, and/or public health were asked
to individually apply the draft tool to three hypothetical
project scenarios that covered a range of content areas,
methodological approaches and participant populations.
The panel members then came together to discuss their
responses with us and comment on the validity, compre-
hensiveness, and clarity of the measure, and to suggest
scores for each item corresponding to the perceived
degree of associated risk. Panel members assigned scores
of 0, 1, 2 or 3 to each fixed response, to correspond with
different levels of ethics review (see Table 1). Differences
in opinion were resolved through discussion and con-
sensus. The expert review panel identified potential gaps
in comprehensiveness and areas for revision to improve
conceptual clarity.
In keeping with our goal to create a user-friendly tool, it
was important that the final product be as short as possible
without sacrificing comprehensiveness. To achieve this ob-
jective, we analyzed the items to identify generic types of
risk that were applicable across diverse methodological ap-
proaches and program areas in order to consolidate items
if they related to the same generic risk. Using this approach
we developed a taxonomy of risks comprising five broad
risk domains: Sensitivity; Participant Selection; Recruit-
ment and Consent; Data/Sample Collection; Identifiability
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and Privacy Risk; and Commercial Interests. The original
list of items was checked against the revised tool, to con-
firm that all previously identified issues were covered and
gaps addressed. For operational purposes, an administra-
tive domain was also included, to accommodate require-
ments for ethics review, such as those imposed by many
funding agencies that may apply regardless of risk level.
Through this process, a revised, 19-item tool with 5
secondary questions was developed.
Internal stakeholder validation
The revised tool was subject to several rounds of testing
and revisions with PHO staff to evaluate the Risk
Screening Tool and comment on its comprehensiveness,
user-friendliness, clarity, and scope. In the first round of
reviews the tool was tested by three research operations
staff members using the three hypothetical scenarios
used for the expert panel discussion, and two staff scien-
tists, using their own projects. The feedback from the five
reviewers was used to revise the tool. In the next round,
the tool was tested on ten different PHO projects from
across program areas (e.g., infectious diseases, health
promotion, environmental health and public health
laboratories) by two research administrators who each
appraised five projects. The tool was revised and then
reviewed by an additional three PHO staff members with
experience in epidemiology, evaluation, infection control
and project management. At this point, the process of in-
ternal review and revision was concluded as no new risks
were being identified (construct saturation), items had
been explicated clearly, and we had reached consensus
regarding the assignment of scores for each item.
External validation
Following internal appraisal at PHO, representatives from
four local public health agencies across the province of
Ontario, Canada were also invited to test and review the
tool. Reviewer recommendations were synthesized and
used to further refine the tool. Similar to the internal
appraisal process, assessments with external stakeholders
continued iteratively until we were satisfied that all items
on the tool were clearly articulated and that the scores for
each item were appropriate.
Pilot testing of the draft tool
The final version of the tool was pilot tested with a
diverse range of projects (e.g., research, surveillance,
program evaluation) as part of the launch of PHO’s new
integrated ethics review system [19]. In the first year of
use, 55 completed Risk Screening Tools were submitted.
The administrative burden for implementing the tool was
found to be minimal, as a result of the user-completion
and automatic scoring features of the tool.
A survey was distributed to PHO scientific and program
staff to evaluate the tool, and 22 staff with experience using
the tool responded. Time to complete the tool ranged form
five to 75 min, with 73 % of respondents taking 20 min or
less. Approximately half (47 %) of applicants completed
the tool as part of a team of three or more, while 33 %
completed the tool on their own. Ninety-one percent of
respondents agreed or strongly agreed that the tool was
“helpful” and “easy to understand”, although suggestions
were offered for clarification of specific items. Respondents
were less likely to find the tool “easy to answer” (74 %);
comments regarding this question indicated that the tool
is appropriate at prompting reflection about risk, but in
some cases presented challenges in aligning some items
and response options with certain projects.
The results of the user survey, as well as observations by
the ethics office regarding items that were associated with
misinterpretations or questions from applicants, were
used to inform a refinement of the tool. As with the first
draft, the revised tool was tested by ethics staff and users
and further refined after each round of feedback.
Results
The resultant PHO Risk Screening Tool (RST 2.0) is an
electronic tool, comprising 20 fixed-response items de-
signed to identify potential risks associated with a project
and determine what level of ethics review is required, if
any (see Additional file 1). The tool features an easy to use
checklist format and is intended to be completed electron-
ically by anyone on the project team who is familiar with
the details of the project. Supplementary information (e.g.,
Table 1 Summary of attributable risk and review levels for each
PHO risk screening tool score
Score Description of risk Level Review level
0 No risks identified Archive
RST catalogued by ethics
office, projects receive
periodic audit.
1 Activity appears to be very low
risk. Alternatives to ethics board
review may be appropriate.
Level 1 Delegated Review
Delegated review by single
reviewer; no completion of
separate application form.
2 Activity appears to be
minimal risk
Delegated ethics review
Completion of full ethics
review board application
form required.
Review completed by two or
more ethics review board
members.
3 Activity appears to be greater
than minimal risk
Full board ethics review
Completion of full ethics
review board application
form required.
Review completed by full
ethics review board.
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definitions, clarifications) is available by holding the com-
puter cursor over highlighted text. Once all 20 items have
been completed, the PHO Risk Screening Tool generates
a risk score and provides a suggested level of ethics
review. The Risk Screening Tool has two main functions;
as an educational tool and as a tool to help sort projects
according to risk.
The Risk Screening Tool can serve as an educational
tool for investigators and reviewers by helping to increase
awareness about the risks that might be associated with
health-related evidence-generating initiatives. The Risk
Screening Tool can be used at any stage in the planning
or implementation of a project and can help encourage
ethical reflection among investigators and other project
team members. Even for those who are very familiar with
the types of risks that may arise, the use of a tool can help
ensure that risks are considered systematically.
To support the sorting of projects according to risk
level, each of the fixed responses has been assigned a risk
level ranging from zero to three. The final score is based
on a threshold rather than a cumulative approach. Use of
a risk threshold ensures that the final score generated by
the PHO Risk Screening Tool will be representative of the
highest level of risk identified in any of the five domains of
the tool. For instance, if at least one of the responses is
scored as “1”, and none of the other responses receive a
higher score of “2” or “3”, then the final risk score gener-
ated by the tool will be “1”. However, if one or more of the
responses corresponded to a risk level of “2”, then the final
score would be “2”. The same threshold procedure applies
for scores of “0” and “3” whereby the highest level of risk
identified, even for a single item, is automatically applied
as the final risk score. To reduce the potential influence of
score information on user response, these values are not
visible to the user (see Additional file 1 for the values asso-
ciated with each response). The Risk Screening Tool pro-
vides guidance to assess the risk associated with a project.
Final determination of risk level involves a “validation”
step by the research ethics committee (e.g., research ethics
board) Chair or delegate to ensure that the assigned
review level is appropriate.
The four risk levels (i.e., “0”, “1”, “2”, “3”) identified by
the Risk Screening Tool are assigned to different levels
of ethical scrutiny, proportionate to the perceived risk
(see Table 1). At PHO, we implemented an ethics review
process that aims to streamline the review of projects
with very low risks or no identified risks (projects scor-
ing “1” or “0”, respectively, on the tool) while ensuring
adequate levels of review for projects that may be associ-
ated with increased concern (e.g., projects scoring “2” or
“3” on the tool). The review process is also compliant
with the existing regulatory requirements, which are
based on the traditional research-practice distinction
paradigm. Projects receiving a score of “2” or “3” are
reviewed by our institutional ethics review board (ERB),
in a process that is consistent with the traditional prac-
tice for projects identified as research [20].
Discussion
Implementation of a paradigm shift away from the prevail-
ing distinction between research and non-research en-
deavors requires practical solutions to ensure appropriate
risk management practices and ethical scrutiny are main-
tained. The PHO Risk Screening Tool was developed to
facilitate this process through the systematic consideration
of risks and the subsequent assignment of proportionate
ethics review. The tool has been validated by both internal
and external stakeholders representing broad areas of
expertise. To date, experiences with the tool confirm that
it is appropriate, efficient, and easy to use. Consequently,
we believe that the PHO Risk Screening Tool re-
presents a useful and robust measure for appraising risk
associated with evidence-generating initiatives in
health-related contexts.
As to be expected with the creation of any novel tool,
numerous factors served to challenge and facilitate the de-
velopment process. First, given the diverse range of project
types and methods employed across health-related sectors,
it was imperative that the tool be comprehensive enough
to capture salient risk-related concerns, but also concise
enough to prevent feelings of burden by users. The chal-
lenge of striking this balance between brevity and scope
was addressed by structuring the tool according to general
risk domains rather than specific project types. The
iterative development and validation processes involving
extensive input from stakeholders, service users, and
subject matter experts helped to ensure salience and
comprehensiveness.
The PHO Risk Screening Tool was developed and vali-
dated in a public health setting, which spans a wide variety
of content areas (e.g., infectious diseases, chronic diseases
and injuries, environmental and occupational health,
emergency preparedness, and health promotion), methods
of inquiry (e.g., epidemiological surveillance, public health
laboratories, program evaluation, among others), and dis-
ciplinary backgrounds (e.g., medicine, nursing, laboratory
sciences). The tool was also subject to both internal and
external review by a diverse range of stakeholders and
subject matter experts. Thus, the diverse setting in which
the tool was developed and the broad experiences of the
tools’ contributors may enhance the generalizability and
applicability of the tool to broader settings.
The Risk Screening Tool is reflective of the widely ac-
cepted bioethical principles of respect for persons, benefi-
cence, non-maleficence, and to a lesser extent, justice, and
so we expect it to be consistent with the conceptualization
of risk in other organizations, provinces and countries.
The questions in the tool are consistent with concerns
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identified, for example, in the US regulations for human
subjects research, 45CFR46 [23], and the ethics screening
questionnaire developed by Massey University, New
Zealand [24], such as protection of vulnerable partici-
pants, the importance of informed consent where appro-
priate, and protection of privacy. Similarly, the concept of
proportionate review, where the level of ethical scrutiny
depends on the risk to participants, is widely accepted,
including by the UK National Health Service [25] and US
federal regulations. Finally, the tool is meant only to iden-
tify potential risks, and to sort projects into one of four
review levels. Institutions are free to assign the action as-
sociated with each level, including the type of review, and
the standards applied in determining the ethical accept-
ability of risks identified. We thus believe that the tool
could be valid in many jurisdictions outside of Canada.
An important goal for this tool was to capture risks to
collectives. As such, we have included items that explicity
flag identifiability of groups, and possible harms arising
from the association of communities or populations with
stigmatizing results. These types of risks can persist des-
pite use of de-identified or anonymized data. Additional
consideration of risks to collectives is captured indirectly.
For example, where consent is required, the project is
flagged for additional review using our framework for
public health projects [21], which probes about the need
for community engagement. However, we recognize that
future versions of the tool could be further enhanced by
capturing additional risks, such as to a “group’s structure
and function because of engagement in research” [26].
In line with our organization’s conceptual ethics frame-
work [21], the PHO Risk Screening Tool was developed to
permit review of all evidence-based initiatives across the
research-practice continuum. However, it is worth noting
that the tool can also be used within the traditional model
of ethics review, as demonstrated by the fact that the Risk
Screening Tool and accompanying ethics review processes
can be used in conformity with current regulatory require-
ments that are based on the traditional research-practice
distinction [20]. Irrespective of an organization’s guiding
ethical framework, the ability to sort and appraise the po-
tential risks of myriad projects using a single, comprehen-
sive tool remains valuable. Once sorted, the projects can
be processed according to existing institutional structures.
The four-level sorting system offers a number of unique
features to facilitate use of the tool across a broad range of
projects and settings. Application of the Risk Screening
Tool ensures that all evidence-generating initiatives have
undergone some level of ethical scrutiny. Level “0” allows
exemption from further ethics review based on a system-
atic approach that can be documented and evaluated.
Level “1” allows for the introduction of a less-intensive
level of review as an alternative to conventional ethics
board submissions. At PHO level 1 review is completed
by one reviewer—either a qualified ethics office staff
person or an ERB member from a roster of designated
level 1 reviewers—and applicants may submit a simple
project description rather than filling out the review board
application form. This reduces burden on applications
and allows for a turn-around-time of a few days rather
than two or more weeks. Addition of a level 1 review
option for very low risk projects provides an in-between
option, avoiding the all-or-none situation of either no
ethics review or formal review committee submission for
delegated or full board review.
Ultimately, we sought to create a tool that identifies
risks associated with evidence-generating initiatives that
could be generalizable to diverse health-related settings
(e.g., learning health care organizations) and applied at
any stage in the review process. Since the tool is system-
atically applied to all initiatives, it eliminates the need to
determine whether a project fits the definition of
“research” and therefore would be subject to research
ethics review. Consequently, it also provides investiga-
tors with documentation of ethics oversight for all
health-related evidence-generating initiatives. Minimally,
the PHO Risk Screening Tool promotes the systematic
assessment of potential risks. It is our hope that the tool
will facilitate consideration of ethical concerns early on
and by shifting the focus to risk rather than project type,
will foster a culture of ethical integrity rather than one
of merely compliance.
Directions for future research
As with the development of any novel tool or organi
zational process, a number of directions for future re-
search warrant consideration. First, because the PHO
Risk Screening Tool was developed and validated in a
Canadian public health setting, additional validation in
diverse settings is recommended to verify the external
validity of the Risk Screening Tool in other settings and
regions. Moreover, given that the tool was developed in
the absence of a gold standard for scoring or appraising
the level of risk associated with diverse health-related
evidence-generating initiatives, we invite feedback on the
scores assigned to each fixed response in the PHO Risk
Screening Tool.
Conclusion
Efforts to facilitate a paradigmatic shift from the prevailing
distinction between research and non-research endeavors
are underway [6]. A key factor limiting the implementa-
tion of this shift in ideology is the question of how to en-
sure appropriate risk management and ethical oversight of
evidence-generating initiatives. The PHO Risk Screening
Tool offers a practical solution to the problem of how to
maintain accountability and appropriate risk oversight that
transcends the boundaries of research and practice. We
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hope that the PHO Risk Screening Tool will prove useful
in minimizing the problems of over and under protection
across a wide range of disciplines and jurisdictions.
Availability and requirements
Project name: Public Health Ontario Risk Screening Tool
Project home page: http://www.publichealthontario.ca/
en/ServicesAndTools/ResearchAndEducationSupport/
Pages/Ethics-support-forms-and-tools.aspx
Operating system: Platform independent
Programming language: Javascript
Other requirments: JavaScript enabled browser, IE8+ or
any modern browser (Chrome, Firefox, Safari)
License: None
Any restrictions to use by non-academics: Non-
commercial use only. Please credit Public Health
Ontario. No modification without permission.
Additional file
Additional file 1: Public Health Ontario Risk Screening Tool 2.0.
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